Involvement of human cytochrome P450 2B6 in the ω- and 4-hydroxylation of the anesthetic agent propofol

Xenobiotica

Volumn 37, Issue 7, 2007, Pages 717-724

  Murayama, N ^a   Minoshima, M ^a   Shimizu, M ^a   Guengerich, F P ^b   Yamazaki, H ^a  

^a SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

2,6 diisopropylphenol; CYP1A2; CYP2B6; CYP3A4; Propofol hydroxylation

Indexed keywords

4 HYDROXYPROPOFOL; ALPHA NAPHTHOFLAVONE; ANESTHETIC AGENT; COMPLEMENTARY DNA; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; OMEGA HYDROXYPROPOFOL; PROPOFOL; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HYDROXYLATION; HUMAN; HUMAN CELL; LIVER MICROSOME; OXIDATION; PROTEIN EXPRESSION;

ANESTHETICS, INTRAVENOUS; ARYL HYDROCARBON HYDROXYLASES; HUMANS; HYDROXYLATION; MICROSOMES, LIVER; PROPOFOL; STEROID HYDROXYLASES;

EID: 34447343580     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250701449431     Document Type: Article

References (28)

1. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ. 1995. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25:261-270.
2. Bray RJ. 1998. Propofol infusion syndrome in children. Paediatric Anaesthesia 8:491-499.
3. Bryson HM, Fulton BR, Faulds D. 1995. Propofol. An update of its use in anaesthesia and conscious sedation. Drugs 50:513-559.
4. Court MH, Duan SX, Hesse LM, Venkatakrishnan K, Greenblatt DJ. 2001. Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology 94:110-119.
5. Favetta P, Dufresne C, Desage M, Paisse O, Perdrix JP, Boulieu R, Guitton J. 2000. Detection of new propofol metabolites in human urine using gas chromatography/mass spectrometry and liquid chromatography/mass spectrometry techniques. Rapid Communications in Mass Spectrometry 14:1932-1936.
6. Guengerich FP. 1995. Human cytochrome P450 enzymes. In: Oritiz de Montellano P.R., editor. Cytochrome P450. New York: Kluwer Academic/Plenum Press.
7. Guitton J, Buronfosse T, Desage M, Flinois JP, Perdrix JP, Brazier JL, Beaune P. 1998. Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. British Journal of Anaesthesia 80:788-795.
8. Hamaoka N, Oda Y, Hase I, Mizutani K, Nakamoto T, Ishizaki T, Asada A. 1999. Propofol decreases the clearance of midazolam by inhibiting CYP3A4: An in vivo and in vitro study. Clinical Pharmacology and Therapeutics 66:110-117.
9. Komatsu T, Yamazaki H, Asahi S, Gillam EMJ, Guengerich FP, Nakajima M, Yokoi T. 2000. Formation of a dihydroxy metabolite of phenytoin by human liver microsomes/cytosol: Roles of cytochrome P450 2C9, 2C19, and 3A4. Drug Metabolism and Disposition 28:1361-1368.
10. McKillop D, Wild MJ, Butters CJ, Simcock C. 1998. Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica 28:845-853.
11. Mandsager RE, Clarke CR, Shawley RV, Hague CM. 1995. Effects of chloramphenicol on infusion pharmacokinetics of propofol in greyhounds. American Journal of Veterinary Research 56:95-99.
12. Mimura M, Baba T, Yamazaki H, Ohmori S, Inui Y, Gonzalez FJ, Guengerich FP, Shimada T. 1993. Characterization of cytochrome P450 2B6 in human liver microsomes. Drug Metabolism and Disposition 21:1048-1056.
13. Navapurkar VU, Skepper JN, Jones JG, Menon DK. 1998. Propofol preserves the viability of isolated rat hepatocyte suspensions under an oxidant stress. Anesthesia and Analgesia 87:1152-1157.
14. Oda Y, Hamaoka N, Hiroi T, Imaoka S, Hase I, Tanaka K, Funae Y, Asada A. 2001. Involvement of human liver cytochrome P4502B6 in the metabolism of propofol. British Journal Clinical Pharmacology 51:281-285.
15. Omura T, Sato R. 1964. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. Journal of Biological Chemistry 239:2370-2378.
16. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics 270:414-423.
17. 14C-propofol after intravenous dosing to rat, dog and rabbit. Xenobiotica 21:1243-1256.
18. Sneyd JR, Simons PJ, Wright B. 1994. Use of proton NMR spectroscopy to measure propofol metabolites in the urine of the female Caucasian patient. Xenobiotica 24:1021-1028.
19. Spatzenegger M, Wang QM, He YQ, Wester MR, Johnson EF, Halpert JR. 2001. Amino acid residues critical for differential inhibition of CYP2B4, CYP2B5, and CYP2B1 by phenylimidazoles. Molecular Pharmacology 59:475-484.
20. Tanaka E, Takano Y, Inomata S, Toyooka H, Honda K. 2004. Premedication medicines do not cause drug metabolic interaction with propofol using human liver microsomes in vitro. European Journal of Clinical Pharmacology 60:565-568.
21. Tsuchiya K, Gatanaga H, Tachikawa N, Teruya K, Kikuchi Y, Yoshino M, Kuwahara T, Shirasaka T, Kimura S, Oka S. 2004. Homozygous CYP2B6*6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochemical and Biophysical Research Communications 319:1322-1326.
22. Yamazaki H, Inoue K, Hashimato M, Shimada T. 1999a. Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Archives of Toxicology 73:65-70.
23. Yamazaki H, Shibata A, Suzuki M, Nakajima M, Shimada N, Guengerich FP, Yokoi T. 1999b. Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P450 2C8 and P450 3A4 in human liver microsomes. Drug Metabolism and Disposition 27:1260-1266.
24. Yamazaki H, Nakamura M, Komatsu T, Ohyama K, Hatanaka N, Asahi S, Shimada N, Guengerich FP, Shimada T, Nakajima M, . 2002. Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. Protein Expression and Purification 24:329-337.
25. Yamazaki H, Okayama A, Imai N, Guengerich FP, Shimizu M. 2006a. Interindividual variation of cytochrome P450 2J2 expression and catalytic activities in liver microsomes from Japanese and Caucasian populations. Xenobiotica 36:1201-1209.
26. Yamazaki H, Shimizu M, Nagashima T, Minoshima M, Murayama N. 2006b. Rat cytochrome P450 2C11 in liver microsomes involved in oxidation of anesthetic agent propofol and deactivated by prior treatment with propofol. Drug Metabolism and Disposition 34:1803-1905.
27. Yan Z, Zhong HM, Maher N, Torres R, Leo GC, Caldwell GW, Huebert N. 2005. Bioactivation of 4-methylphenol (p-cresol) via cytochrome P450-mediated aromatic oxidation in human liver microsomes. Drug Metabolism and Disposition 33:1867-1876.
28. Yoshitomi S, Ikemoto K, Takahashi J, Miki H, Namba M, Asahi S. 2001. Establishment of the transformants expressing human cytochrome P450 subtypes in HepG2, and their applications on drug metabolism and toxicology. Toxicology in Vitro 15:245-256.